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An infection with Cryptosporidium felis in an HIV-positive man
from Italy was successfully treated with paromomycin, despite
the patient’s having a CD4+ cell count of 31/mm3. Fourteen
cases of human infection with C. felis have been described, all
in the past 3 years, emphasizing the public health importance of
Cryptosporidium parasites other than C. parvum.
arasites belonging to the genus  Cryptosporidium are an
important and widespread cause of enteric disease in
humans and in many other vertebrates. The most commonly
identified etiologic agent of human cryptosporidiosis is
Cryptosporidium parvum (1), which, based on the molecular
characterization of oocysts, can be divided into two genetically
distinct subpopulations: genotype 1 (or the “anthroponotic gen-
otype”), which is associated exclusively with human infection;
and genotype 2 (the “zoonotic genotype”), which is associated
with both human and animal infection (2). For many years, C.
parvum was considered to be the only etiologic agent of human
infection. However, the use of molecular tools with a greater
capacity to detect and differentiate strains has resulted in the
identification of other human pathogens: C. felis, C. meleagri-
dis, the C. parvum dog genotype, and possibly C. muris (2).
In Italy, all Cryptosporidium oocysts detected in immuno-
competent and immunosuppressed persons have been identi-
fied as  C. parvum (3). In this report, we describe the first
Italian case of a human C. felis infection, which occurred in an
HIV-positive man who, in spite of a very low CD4+ cell count,
successfully recovered with paromomycin treatment.
The Study
On December 12, 2000, a 42-year-old homosexual man
with severe diarrhea was admitted as an outpatient to the
Umberto I° University Medical Center in Rome, Italy. The
man had been diagnosed with Hepatitis B virus infection in
1982 and with HIV infection in 1988. In 1989, his CD4+ cell
count had reached 189/mm3, and he started antiretroviral ther-
apy with zidovudine. He was later treated with all nucleoside
analogs (individually or combined), and in 1996 he began
treatment with highly active antiretroviral therapy (HAART).
The specific HAART regimen was changed several times
because of his poor immunologic and virologic response. In
the course of years, the man had many episodes of oral candid-
iasis, which were responsive to fluconazole therapy. In July
2000, he weighed 87 kg and had a CD4+cell count of 52/mm3;
at that time, HAART was changed to include ritonavir, indi-
navir, stavudine, and didanosine. In November 2000, the
patient had isolated episodes of diarrhea, but feces were not
investigated for the presence of parasites. At the beginning of
December 2000, he was affected by impetigo, which was
treated with erythrocine (1800 mg/day). Two days after begin-
ning that therapy, he began to have up to 10 episodes of diar-
rhea per day. Erythrocine was interrupted after 3 days, and, in
the period of 1 week, the patient lost 9 kg. Stool specimens
were tested for a wide panel of enteric pathogens (bacteria,
viruses, helminths, and protozoa, including microsporidia).
The parasitologic examination of stools showed Cryptosporid-
ium oocysts (3x106 oocysts/mL of feces). The oocyst diameter
was in the range of 4.5-4.9 mm. Oocysts reacted strongly with
two monoclonal antibodies conjugated with fluorescein (Meri-
Fluor, Meridian Diagnostics, Cincinnati, OH;  Cryptosporid-
ium Immunofluorescence Test, Microgen Bioproducts Ltd,
UK). No other pathogen was found in the specimens. The
patient was treated with paromomycin (1 g, 3 times/day). On
the second day of treatment, the diarrhea promptly resolved,
decreasing from 10 to 2 bouts per day. Paromomycin treatment
was continued until mid-February (CD4+ cell count 31/mm3)
without further diarrheal episodes, and stools were negative for
Cryptosporidium.
DNA was extracted from the whole feces according to the
FastPrep method of da Silva et al. (4), and the diagnostic frag-
ment of the small subunit ribosomal RNA (ssu-rRNA) was
amplified by polymerase chain reaction (PCR) with the primer
set CPBDIAGF and CPBDIAGR (5). The sequence of the
PCR product was determined, and a comparison with all ssu-
rRNA  Cryptosporidium sequences available in databanks
revealed 100% similarity with the homologous fragment of C.
felis (accession number AF087577). To obtain additional
information on the nature of the species, a PCR-restriction
fragment length polymorphism assay (primer set cry9 and
cry15) (6) that targets a fragment of a Cryptosporidium oocyst
wall protein gene was used (7). This second analysis con-
firmed the identification of C. felis (Figure).
To the best of our knowledge, this is the only case of a C.
felis infection for which the clinical course and the response to
therapy have been reported. Although the literature contains
numerous reports of paromomycin treatment of human
Cryptosporidium infection, the results regarding the efficacy
of paromomycin are contrasting, possibly because it was
always assumed that the etiologic agent was C. parvum. The
current knowledge that several species and genotypes  can
infect humans suggests that the efficacy of paromomycin could
depend on the specific Cryptosporidium species/genotype and
its susceptibility to this drug. In our case report, the infected per-
son had a very low CD4+ count, which has been considered as
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one of the most important factors in the failure of paromomycin
treatment (8,9). The concomitance of the erythrocine treatment
and severe watery diarrhea suggests that the drug had altered
the intestinal flora and, in turn, favored the growth of the para-
site. A concomitant influence of paromomycin treatment and
the interruption of erythrocine treatment can be also postulated.
There have been 14 cases of human infections with C. felis
reported; all have occurred in the past 3 years (10-13). These
cases occurred in North and South America, Africa, and
Europe, and they involved both immunocompetent (n=4) and
immunosuppressed (n=10) persons.
There have also been cases of human cryptosporidiosis in
which cats were identified as the source for human infection,
yet the species of Cryptosporidium remained unknown. Glaser
et al. (14) examined the association between Cryptosporidium
infection and animal exposure in HIV-infected persons and
concluded that only dog ownership presents a risk, although
minimal; no significant risk was associated with cat ownership.
However, cats have been successfully experimentally infected
with C. parvum oocysts of human and bovine origin, and a C.
felis infection of a cow has been demonstrated (15). These data
show not only that the host specificity of some of the
Cryptosporidium species that infect mammals is less restricted
than previously thought but also that there is a complex circu-
lation of species in the environment. Under such circum-
stances, it is often difficult to trace the source of an infection.
In our case, the C. felis-infected person did not have a cat at
home, but the city where he lives (Rome) is home to a plethora
of stray and domestic cats (approximately 0.1 cat per inhabit-
ant). Infection may have occurred upon accidental contact with
oocysts in the environment. The public health importance of
Cryptosporidium parasites other than C. parvum needs to be
assessed.
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Figure. Electrophoretic separation of Cryptosporidium oocyst wall pro-
tein gene-polymerase chain reaction products digested with the endo-
nuclease  RsaI. Lane M, 50-bp size ladder; CpH,  Cryptosporidium
parvum human genotype; CpC C. parvum calf genotype; Cw, C. wrairi;
Cf, C. felis; Cb, C. baileyi; Cs, C. serpentis; Cm, C. muris.